secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0000950170-22-003293
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics reports FY2021 net loss $149.3M; cash to H2 2024; pipeline milestones outlined
--------------------------------------------------------------------------------

- Net loss of $149.3M for 2021 ($2.93/share) vs $59.4M in 2020; R&D spend $121.3M.
- Cash, equivalents and securities $376.6M at Dec 31, 2021; cash runway into second half 2024.
- FDA response for DYNE-251 IND in DMD expected Q2 2022; patient dosing in Phase 1/2 planned mid-2022.
- Regulatory filings for DYNE-101 in DM1 in multiple countries planned Q2 2022 with mid-2022 trial start.
- IND for DYNE-301 in FSHD expected in second half of 2022; board appointment of Carlo Incerti, M.D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017022003293/0000950170-22-003293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017022003293/dyn-20220310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-003293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer